Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy
- 11 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 34 (12), 3420-3425
- https://doi.org/10.1038/s41375-020-0851-8
Abstract
Patients receiving an allogeneic hematopoietic cell transplantation (allo-HCT) after the use of PD-1 inhibitors seem to be at a higher risk of developing acute graft-versus-host disease (aGHVD) through etiopathogenetic mechanisms not fully elucidated. Herein, we investigated the effect of nivolumab administered prior to allo-HCT on the following early T-cell reconstitution and its modulation by the GVHD prophylaxis (tacrolimus/sirolimus vs. posttransplant cyclophosphamide [PTCY]). In all nivolumab-exposed patients we detected circulating nivolumab in plasma for up to 56 days after allo-HCT. This residual nivolumab was able to bind and block PD-1 on T-cells at day 21 after allo-HCT, inducing a T cell activation that was differentially modulated depending on the GVHD prophylactic regimen. Among patients receiving tacrolimus/sirolimus, nivolumab-exposed patients had a higher incidence of severe aGVHD and a more effector T-cell profile compared with anti-PD-1-naïve patients. Conversely, patients receiving PTCY-based prophylaxis showed a similar risk of aGVHD and T-cell profile irrespective of the previous nivolumab exposure. In conclusion, nivolumab persists in plasma after transplantation, binds to allogeneic T cells and generates an increased T-cell activation. This T-cell activation status can be mitigated with the use of PTCY, thus reducing the risk of aGVHD.Keywords
This publication has 15 references indexed in Scilit:
- PTCy ameliorates GVHD by restoring regulatory and effector T-cell homeostasis in recipients with PD-1 blockadeBlood Advances, 2019
- Posttransplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppressionJCI Insight, 2019
- The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin’s LymphomaBone Marrow Transplantation, 2019
- Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamideBlood Advances, 2018
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 TrialJournal of Clinical Oncology, 2018
- Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphomaBlood, 2017
- Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamideJCI Insight, 2016
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's LymphomaThe New England Journal of Medicine, 2015
- Aldehyde Dehydrogenase Expression Drives Human Regulatory T Cell Resistance to Posttransplantation CyclophosphamideScience Translational Medicine, 2013
- Blockade of Programmed Death-1 Engagement Accelerates Graft-Versus-Host Disease Lethality by an IFN-γ-Dependent MechanismThe Journal of Immunology, 2003